News Column

SYNTA PHARMACEUTICALS CORP FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders

June 17, 2014

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Company's annual meeting of stockholders on June 12, 2014 (the "Annual Meeting"), at which a quorum was present, the stockholders of the Company voted on and approved the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 30, 2014 (the "Proxy Statement"): (1) to elect Donald W. Kufe, M.D. and William S. Reardon, C.P.A. as Class I directors to each serve for a three-year term expiring at the Company's annual meeting of stockholders in 2017, and until their successors have been elected and qualified, or until their earlier death, resignation, retirement or removal ("Proposal 1"); (2) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014 ("Proposal 2"); and (3) to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement ("Proposal 3").

The tabulation of votes with respect to the proposals was as follows:

Proposal 1 - Election of Directors:

For Withheld Broker Non-Votes Donald W. Kufe, M.D. 44,773,246 225,085 29,966,053 William S. Reardon, C.P.A. 44,786,542 211,789 29,966,053

Proposal 2 - Ratification of Independent Registered Public Accounting Firm:

For Against Abstain 74,647,455 269,002 47,927

Proposal 3 - Advisory Vote on Approval of Executive Compensation:

For Against Abstain Broker Non-Votes 43,066,203 1,783,865 148,263 29,966,053 2


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses